Lifeboat Foundation

Losing hair can be a distressing experience for many people, but treatments are often ineffective, expensive or riddled with side effects. Could this development change that?

A study from Colombia University has shown blocking a certain family of enzymes can rapidly restore hair. The enzymes are called the Janus kinase (JAK) family, and two drugs have already been approved for blood diseases (ruxolitinib) and rheumatoid arthritis (tofacitinib), and are also undergoing other clinical trials.

Read more

Viruses are usually thought of as agents of disease. But for the first time, scientists are poised to bring to the US market a virus that can help thwart cancer, a development that could herald a new age of viral therapies.

Approved by the Food and Drug Administration on Tuesday for treating advanced-stage melanoma, the virus — called Imlygic, which was developed in part in a Massachusetts lab — is a modified version of the herpes virus that both attacks the cancer and sparks the immune system into action against tumors.

In clinical trials, it has helped some cancer patients achieve remission with few of the nasty side effects common to existing treatments. And as the first tumor-killing virus to receive the FDA’s blessing, Imlygic could accelerate the development of other viral therapies.

Read more

https://www.youtube.com/watch?v=O9dj1s3N4cE

Adam Alonzi has made another excellent film about the power of gene therapy.

Narrated and produced by Adam Alonzi. Music arranged by Leslee Frost. Sponsored by BioViva Sciences Inc.

Continue reading “BioViva Presents: Alzheimer’s Disease and Gene Therapy” »

Coronary artery structure being 3-D bioprinted (credit: Carnegie Mellon University College of Engineering)

Carnegie Mellon scientists are creating cutting-edge technology that could one day solve the shortage of heart transplants, which are currently needed to repair damaged organs.

“We’ve been able to take MRI images of coronary arteries and 3-D images of embryonic hearts and 3-D bioprint them with unprecedented resolution and quality out of very soft materials like collagens, alginates and fibrins,” said Adam Feinberg, an associate professor of Materials Science and Engineering and Biomedical Engineering at Carnegie Mellon University.

Read more

http://dilbert.com/strip/2015-10-25

Read more

That was the year she learned to control a Nexus tablet with her brain waves, and literally took her life quality from 1980s DOS to modern era Android OS.

A brunette lady in her early 50s, patient T6 suffers from amyotrophic lateral sclerosis (also known as Lou Gehrig’s disease), which causes progressive motor neuron damage. Mostly paralyzed from the neck down, T6 retains her sharp wit, love for red lipstick and miraculous green thumb. What she didn’t have, until recently, was the ability to communicate with the outside world.

Read more

Nice interview by The Longevity Reporter about BioViva Sciences Inc.

Liz Parrish isn’t your average CEO. A passionate advocate for change, her.
company BioViva is leading the fight for healthy longevity with pioneering.
gene therapies targeting Alzheimer’s, sarcopenia and even aging itself.
Parrish dreams big, but she’s a woman of action. She’s even demonstrated.
her commitment by testing cutting-edge therapies on herself. Could her.
efforts change how we think about aging? Is gene therapy the future or are.
we moving too fast? We caught up with the woman herself to find out more.

Read more

After a 10 year study of 3000 people, researchers have made the surprising discovery that hearts age differently in men and women.

We need personalised medicine

We know people age differently, both inside and outside. This is down to a complex interplay of genetics and environment, which leads to significant variation in the aging process for all of us. What we didn’t expect was that such a striking difference would emerge between the genders. So what does this mean? Could there be more we’re missing?

Read more

As of this month, over 4,000 Americans are on the waiting list to receive a heart transplant. With failing hearts, these patients have no other options; heart tissue, unlike other parts of the body, is unable to heal itself once it is damaged. Fortunately, recent work by a group at Carnegie Mellon could one day lead to a world in which transplants are no longer necessary to repair damaged organs.

“We’ve been able to take MRI images of coronary arteries and 3-D images of embryonic hearts and 3-D bioprint them with unprecedented resolution and quality out of very soft materials like collagens, alginates and fibrins,” said Adam Feinberg, an associate professor of Materials Science and Engineering and Biomedical Engineering at Carnegie Mellon University. Feinberg leads the Regenerative Biomaterials and Therapeutics Group, and the group’s study was published in the October 23 issue of the journal Science Advances. A demonstration of the technology can be seen below.

“As excellently demonstrated by Professor Feinberg’s work in bioprinting, our CMU researchers continue to develop novel solutions like this for problems that can have a transformational effect on society,” said Jim Garrett, Dean of Carnegie Mellon’s College of Engineering. “We should expect to see 3-D bioprinting continue to grow as an important tool for a large number of medical applications.”

Read more